Goldman Sachs Group Inc Neoleukin Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 May 14, 2024	SELL	$0.69 - $1.33 $16,572 - $31,943	-24,018 Reduced 60.41%	15,741 $10,000
Q3 2022 Nov 10, 2022	SELL	$0.69 - $1.33 $16,572 - $31,943	-24,018 Reduced 60.41%	15,741 $0
Q2 2022 May 14, 2024	BUY	$0.92 - $2.25 $36,578 - $89,457	39,759 New	39,759 $41,000
Q2 2022 Aug 15, 2022	SELL	$0.92 - $2.25 $24,851 - $60,779	-27,013 Reduced 40.46%	39,759 $41,000
Q1 2022 May 16, 2022	BUY	$1.72 - $5.23 $35,905 - $109,176	20,875 Added 45.48%	66,772 $126,000
Q4 2021 Feb 14, 2022	SELL	$4.65 - $7.75 $333,679 - $556,132	-71,759 Reduced 60.99%	45,897 $222,000
Q3 2021 Nov 10, 2021	BUY	$6.05 - $9.66 $711,818 - $1.14 Million	117,656 New	117,656 $850,000

199K

Ticker NLTX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 42,579,900
Description
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of vario...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.